PMV Pharmaceuticals Statistics
Share Statistics
PMV Pharmaceuticals has 51.95M
shares outstanding. The number of shares has increased by 0.95%
in one year.
| Shares Outstanding | 51.95M |
| Shares Change (YoY) | 0.95% |
| Shares Change (QoQ) | 0.36% |
| Owned by Institutions (%) | 75.54% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 11 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 840.93K, so 1.62% of the outstanding
shares have been sold short.
| Short Interest | 840.93K |
| Short % of Shares Out | 1.62% |
| Short % of Float | 1.92% |
| Short Ratio (days to cover) | 3.47 |
Valuation Ratios
The PE ratio is -1.33 and the forward
PE ratio is -0.49.
PMV Pharmaceuticals's PEG ratio is
0.06.
| PE Ratio | -1.33 |
| Forward PE | -0.49 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | 0.44 |
| P/FCF Ratio | -1.5 |
| PEG Ratio | 0.06 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for PMV Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.22,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.22 |
| Quick Ratio | 12.22 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,249,127.66 |
| Employee Count | 47 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -16.1M |
| Effective Tax Rate | 21.52% |
Stock Price Statistics
The stock price has increased by -47.37% in the
last 52 weeks. The beta is 1.5, so PMV Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.5 |
| 52-Week Price Change | -47.37% |
| 50-Day Moving Average | 0.97 |
| 200-Day Moving Average | 1.37 |
| Relative Strength Index (RSI) | 49.13 |
| Average Volume (20 Days) | 181,971 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -85.45M |
| Net Income | -58.71M |
| EBITDA | -73.67M |
| EBIT | -74.81M |
| Earnings Per Share (EPS) | -1.14 |
Full Income StatementBalance Sheet
The company has 40.88M in cash and 1.19M in
debt, giving a net cash position of 39.69M.
| Cash & Cash Equivalents | 40.88M |
| Total Debt | 1.19M |
| Net Cash | 39.69M |
| Retained Earnings | -368.71M |
| Total Assets | 170.61M |
| Working Capital | 153.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -51.28M
and capital expenditures -655K, giving a free cash flow of -51.94M.
| Operating Cash Flow | -51.28M |
| Capital Expenditures | -655K |
| Free Cash Flow | -51.94M |
| FCF Per Share | -1.01 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
